Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Dual-Target Power: Creative Biolabs Launches a One-Stop BsAb Platform for Cancer Therapy

By: Get News
According to Creative Biolabs, they begin their custom development of bispecific antibodies by working together with the researchers to enhance the development of cancer immunotherapy.

New York, USA - November 7, 2024 - "Bispecific antibodies can bind and link two separate antigens simultaneously, bypassing the functional limitations of conventional mAbs," said a Creative Biolabs' representative. "This way, tumor cells can be precisely targeted and immune cells can be effectively turned on to enhance the anti-tumor immune response."

BsAb Development Services

Creative Biolabs possesses unique manufacturing capabilities and extensive experience in creating bispecific antibodies (bsAb). "This is not our first attempt to establish this platform—it's a comprehensive upgrade of our past services, but it has undergone additional re-engineering," the representative emphasized. "Design to bsAb manufacturing interests the clients and provides an all-in-one package."

Customized Design and Engineering

Creative Biolabs provides design services that incorporate the needs of the clients. Designs of bsAbs are conducted using sophisticated computational modeling and experimental methodologies, considering target characteristics and therapeutic objectives to achieve the best possible affinity and certainty of the designed bsAbs. Below are the bispecific antibody formats we provide to our clients:

* Bispecific IgG

* Bispecific fusion proteins

* Appended IgGs

* Bispecific antibody fragments

Purification and Production

The factors that determine the characteristics of the bsAbs include the source from which they were transfected and cultured, and more importantly, high-quality purification. Such variability in the bsAb constructs can be addressed through a wide range of bsAb purification strategies, including recombinant expression, chemical conjugation, and hybridoma technology to meet the individualized requirements of different projects.

"We have tested our production processes in previous successful projects, after which manufactured antibodies have been confirmed to fulfill the requirements of the industry in terms of both quality and functionality."

Functional Analysis and Evaluation

There are several steps that involve detailed functional analysis and examination in the development of bsAb. To achieve this goal, Creative Biolabs utilizes state-of-the-art analytical tools and equipment to evaluate and characterize the biological activity of bsAbs, pharmacokinetic properties, and preclinical efficacy, ensuring that each antibody performs excellently in preclinical studies.

"We need to appreciate how serious and involving cancer is such that the different specialists involved in its research need to be versatile in tackling multiple challenges," the specialist stressed. "The emergence of bsAbs offers scientists new horizons in science and technology."

Thus, Creative Biolabs is also working with research institutes to study the possibilities of developing the next generation of bsAbs, such as trispecific antibodies, prodrug bsAbs, and bsAbs that can trigger the degradation of specific tumor targets, which provide more creative options to cancer therapy.

To know more about the bispecific antibody development solutions, check https://www.creative-biolabs.com/bsab.

About Creative Biolabs

Creative Biolabs is a service provider in the biopharmaceutical industry with a dedicated R&D team and vast experience. Creative Biolabs will keep expanding its efforts in this area to improve its R&D and technology platforms.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/bsab

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.